title: Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients.
abstract: OBJECTIVE
  Extracellular matrix remodeling during tumor growth plays an important role in angiogenesis. Our preclinical data suggest that a newly identified cryptic epitope (HU177) within collagen type IV regulates endothelial and melanoma cell adhesion in vitro and angiogenesis in vivo. In this study, we investigated the clinical relevance of HUI77 shedding in melanoma patient sera.
  
  
  METHODS
  Serum samples from 291 melanoma patients prospectively enrolled at the New York University Medical Center and 106 control subjects were analyzed for HU177 epitope concentration by a newly developed sandwich ELISA assay. HU177 serum levels were then correlated with clinical and pathologic parameters.
  
  
  RESULTS
  Mean HU177 epitope concentration was 5.8 ng/mL (range, 0-139.8 ng/mL). A significant correlation was observed between HU177 concentration and nodular melanoma histologic subtype [nodular, 10.3 +/- 1.6 ng/mL (mean +/- SE); superficial spreading melanoma, 4.5 +/- 1.1 ng/mL; all others, 6.1 +/- 2.1 ng/mL; P = 0.01 by ANOVA test]. Increased HU177 shedding also correlated with tumor thickness (< or =1.00 mm, 3.8 +/- 1.1 ng/mL; 1.01-3.99 mm, 8.7 +/- 1.3 ng/mL; > or =4.00 mm, 10.3 +/- 2.4 ng/mL; P = 0.003 by ANOVA). After multivariate analysis controlling for thickness, the correlation between higher HU177 concentration and nodular subtype remained significant (P = 0.03). The mean HU177 epitope concentration in control subjects was 2.4 ng/mL.
  
  
  CONCLUSIONS
  We report that primary melanoma can induce detectable changes in systemic levels of cryptic epitope shedding. Our data also support that nodular melanoma might be biologically distinct compared with superficial spreading type melanoma. As targeted interventions against cryptic collagen epitopes are currently undergoing phase I clinical trial testing, these findings indicate that patients with nodular melanoma may be more susceptible to such targeted therapies.
authors.affiliation: Department of Dermatology, New York University School of Medicine, 522 First Avenue, New York, NY 10016, USA.
authors.forename: Bruce
authors.initials: B
authors.lastname: Ng
authors.forename: Jan
authors.initials: J
authors.lastname: Zakrzewski
authors.forename: Melanie
authors.initials: M
authors.lastname: Warycha
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Christos
authors.forename: Dean F
authors.initials: DF
authors.lastname: Bajorin
authors.forename: Richard L
authors.initials: RL
authors.lastname: Shapiro
authors.forename: Russell S
authors.initials: RS
authors.lastname: Berman
authors.forename: Anna C
authors.initials: AC
authors.lastname: Pavlick
authors.forename: David
authors.initials: D
authors.lastname: Polsky
authors.forename: Madhu
authors.initials: M
authors.lastname: Mazumdar
authors.forename: Anthony
authors.initials: A
authors.lastname: Montgomery
authors.forename: Leonard
authors.initials: L
authors.lastname: Liebes
authors.forename: Peter C
authors.initials: PC
authors.lastname: Brooks
authors.forename: Iman
authors.initials: I
authors.lastname: Osman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002448:Cell Adhesion; D015331:Cohort Studies; D003094:Collagen / Q000737:chemistry*; D024141:Collagen Type IV / Q000096:biosynthesis* / Q000737:chemistry / Q000378:metabolism; D000939:Epitopes / Q000737:chemistry*; D005109:Extracellular Matrix / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008545:Melanoma / Q000097:blood* / Q000378:metabolism; D008875:Middle Aged; D009369:Neoplasms / Q000378:metabolism; D009389:Neovascularization, Pathologic
chemical_list: D024141:Collagen Type IV; D000939:Epitopes; D003094:Collagen